DLBCL in Focus: Transforming Outcomes With CAR T Therapy

Opinion
Video

Panelists discuss how the diffuse large B-cell lymphoma (DLBCL) treatment landscape has seen significant evolution with the integration of targeted therapies and chimeric antigen receptor T-cell treatments, supplementing traditional R-CHOP. However, early relapsed/refractory cases remain challenging due to complex tumor biology and resistance mechanisms. This underscores the need for better up-front risk stratification tools and biomarker-driven treatment selection.

Recent Videos
2 experts are featured in this series.
5 experts in this video
2 experts are featured in this series.
4 experts in this video
Related Content